Eli Lilly's Weight-Loss Pill Debuts Amid Shifting Market Dynamics

Eli Lilly's oral GLP-1 drug Foundayo is now available across the US. Analysts adjust sales forecasts as competition with Novo Nordisk's Wegovy intensifies ahead of key Q1 earnings.

Eli Lilly’s new weight-loss pill, Foundayo, is now available across the United States, marking a pivotal moment for the pharmaceutical giant. The oral GLP-1 drug, which received FDA approval on April 1, 2026, began shipping to pharmacies on April 9. Its nationwide rollout on April 10 through channels like Amazon Pharmacy, LifeMD, and LillyDirect introduces a more convenient option for patients, as it requires no refrigeration and has no food or drink intake restrictions.

Wall Street’s reaction has been measured. On the day of the launch, RBC Capital maintained its Outperform rating but trimmed its first-year sales forecast for Foundayo to a range of $1.25 to $1.5 billion, down from prior estimates exceeding $2 billion. The firm cited a market shift toward broader access and volume growth, which is expected to pressure pricing. Meanwhile, Morgan Stanley analyst Terence Flynn slightly raised his price target on Eli Lilly shares to $1,327 from $1,313, reaffirming an Overweight rating. His confidence stems from recent commercial data signals and intra-quarter updates ahead of the company's first-quarter earnings report.

The competitive landscape is intensifying. Novo Nordisk brought its oral Wegovy pill to market roughly three months earlier and recently released data suggesting a comparative efficacy advantage. However, analysts note this cross-trial comparison has methodological limitations. William Blair’s Andy Hsieh points out that Foundayo’s lack of dietary restrictions could give it an edge in patient and physician adoption over the rival product with more stringent intake rules. To prevent the supply shortages that plagued earlier injectable GLP-1 drugs, Lilly has built up an initial inventory worth $1.5 billion.

Investor focus now turns to the company's quarterly results scheduled for April 30. This report will provide the first official sales figures for Foundayo, a key test for the drug's early traction. Analysts project first-quarter 2026 adjusted earnings per share of $7.55, more than double the $3.34 reported a year ago. For the full year, Eli Lilly’s own guidance calls for EPS between $33.50 and $35.00, while the consensus estimate stands at $34.73. Some on Wall Street see a long-term peak annual sales potential for Foundayo exceeding $40 billion, though near-term 2026 expectations vary between $1.5 and $2.8 billion.

While expanding in the U.S., Eli Lilly faces headwinds in key international markets. In India, the market share for its tirzepatid-based products fell to 64% in March 2026 from 71% previously, as cheaper semaglutid generics gained ground, capturing 33% of the market. Domestically, the company anticipates low- to mid-single-digit price declines for its products this year but expects significant volume growth to counterbalance that pressure. A potential demand catalyst looms in July 2026, when Medicare Part D is set to begin covering the new oral medications. Currently, Eli Lilly's stock trades approximately 16% below its 52-week high of 959.50 euros.